Significance of continuous surveillance of anti-endothelial cell antibody in patients with chronic obstructive pulmonary disease_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

XUE Huihong ¹ ,  ZHANG Cheng ^1,2 , ZHANG Xiangyan ^1,2 , SHAO Songjun ^1,2 , TIAN Yang ^1,2

1. Department of Respiratory and Critical Care Medicine, Guizhou Provincial People's Hospital, Guiyang, Guizhou 550000, P. R. China;
2. Key Laboratory of Pulmonary Immune Diseases, National Health Commission, Guiyang, Guizhou 550000, P. R. China;

Corresponding?author：

ZHANG Cheng, Email: zhangcheng16@sina.com

Keywords：

Chronic obstructive pulmonary disease; Anti-endothelial cell antibody; Disease progression

DOI：

10.7507/1671-6205.202104013

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To explore the significance of continuous surveillance of anti-endothelial cell antibody (AECA) in patients with chronic obstructive pulmonary disease (COPD) in one year.Methods Thirty-six patients with acute exacerbation of COPD and 93 patients with stable COPD were selected from Guizhou Provincial People's Hospital from October 2019 to February 2020, thirty healthy people in the same period were selected as normal control group. In the stable phase group, >386.17 pg/mL was included in the higher group, and <386.17 pg/mL was included in the lower group according to the AECA median (386.17 pg/mL). According to the grouping criteria, the patient with the AECA median was omitted, the sample size of AECA higher group and lower group accounted for 46 cases, respectively. AECA test, lung function examination, the number of acute exacerbations in the past 1 year and MMRC score were performed for each group; At the same time, all the above contents were followed up dynamically.Results 1. Comparison of AECA levels among the three groups: the acute exacerbation COPD group was higher than the stable phase group and the normal control group, and the stable phase group was higher than the normal control group, with statistical significance (all P<0.05). 2. Overall comparison of related indicators before and after follow-up in COPD stable period group: AECA level was higher than baseline after follow-up, and the follow-up after 12 months was higher than that after 6 months; After 12 months, forced expiratory volume in one second (FEV₁), the ratio of FEV₁ to forced vital capacity (FVC), and FEV₁%pred were all lower than baseline, and the first two indexes were lower than those after 6 months follow-up. The number of acute exacerbations and mMRC score after 12 months were higher than that after 6 months follow-up, with statistical significance (all P<0.05). 3. Comparison of related indicators after follow-up between the higher and lower AECA groups: Follow-up after 12 months showed that AECA, the number of acute exacerbations and mMRC score in the higher AECA group were all higher than those in the lower AECA group at the same period, and the number of acute exacerbations and MMRC score in the higher AECA group were higher than those in the lower AECA group at 6-month follow-up. The FEV₁, FEV₁%pred and FEV₁/FVC of the higher AECA group followed up after 12 months were lower than those of the lower AECA group at the same period, and the FEV₁ and FEV₁%pred of the higher AECA group followed up after 6 months were lower than those of the lower AECA group at the same period, and all the differences were statistically significant (all P<0.05).Conclusion Abnormality of AECA expression in COPD may be associated with continued decline in lung function, number of acute exacerbations in the previous 1 year, and increased mMRC score, and therefore may be associated with continued progression.

Citation： XUE Huihong, ZHANG Cheng, ZHANG Xiangyan, SHAO Songjun, TIAN Yang. Significance of continuous surveillance of anti-endothelial cell antibody in patients with chronic obstructive pulmonary disease. Chinese Journal of Respiratory and Critical Care Medicine, 2021, 20(8): 536-541. doi: 10.7507/1671-6205.202104013 Copy

1.	Vogelmeier CF, Criner GJ, Martínez FJ, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. Arch Bronconeumol, 2017, 53(3): 128-149.
2.	Cheng G, Zhang N, Wang Y, et al. Antibodies of IgG, IgA and IgM against human bronchial epithelial cell in patients with chronic obstructive pulmonary disease. Clin Lab, 2016, 62(6): 1101-1108.
3.	Scambler T, Holbrook J, Savic S, et al. Autoinflammatory disease in the lung. Immunology, 2018, 154(4): 563-573.
4.	Wen L, Krauss ES, Petersen F, et al. Autoantibodies in chronic obstructive pulmonary disease. Front Immunol, 2018, 25(9): 66.
5.	韋薇, 沈雅萍, 楊翌翔, 等. 血清中抗內皮細胞抗體檢測對狼瘡性腎炎患者的價值. 國際檢驗醫學雜志, 2017, 38(6): 822-824.
6.	Moroncini G, Svegliati BS, Gabrielli A. Agonistic antibodies in systemic sclerosis. Immunol Lett, 2018, 195: 83-87.
7.	馬麗, 張璐, 張程, 等. 抗血管內皮細胞抗體在吸煙肺氣腫大鼠肺泡隔細胞凋亡中的作用及甲潑尼龍的干預效果. 廣東醫學, 2016, 37(10): 1447-1450.
8.	李佳藝, 張程, 李本雪, 等. 甲潑尼龍琥珀酸鈉對自身免疫性肺氣腫模型大鼠氧化應激和抗內皮細胞抗體的影響. 中國藥房, 2020, 31(10): 1208-1212.
9.	劉磊. 系統性紅斑狼瘡患者血清蛋白 S 與生長阻抑特異性蛋白 6 水平變化及與疾病活動度的相關性研究. 臨床和實驗醫學雜志, 2015, 14(24): 2052-2054.
10.	王艷, 陳燕, 季黎明, 等. 不同血清 25-羥維生素 D 水平的 2 型糖尿病患者頸動脈內膜中層厚度的變化. 臨床和實驗醫學雜志, 2016, 15(5): 445-447.
11.	中華醫學會呼吸病學分會慢性阻塞性肺疾病學組. 慢性阻塞性肺疾病診治指南(2013 年修訂版). 中華結核和呼吸雜志, 2013, 36(4): 255-264.
12.	Legendre P, Régent A, Thiebault M, et al. Anti-endothelial cell antibodies in vasculitis: a systematic review. Autoimmun Rev, 2017, 16(2): 146-153.
13.	Karayama M, Inui N, Suda T, et al. Antiendothelial cell antibodies in patients with COPD. Chest, 2010, 138: 1303-1308.
14.	包海鵬, 史琦, 閻玥, 等. 分子生物學標志物在 COPD 發病機制中的作用研究概況. 遼寧中醫雜志, 2019, 46(6): 1334-1338.
15.	Taraseviciene SL, Douglas IS, Nana-Sinkam PS, et al. Is alveolar destruction and emphysema in chronic obstructive pulmonary disease an immune disease?. Proc Am Thorac Soc, 2006, 3(8): 687-690.
16.	Neder JA, de-Torres JP, Milne KM, et al. Lung function testing in chronic obstructive pulmonary disease. Clin Chest Med, 2020, 41(3): 347-366.
17.	Breen M, Nwanaji-Enwerem JC, Karrasch S, et al. Accelerated epigenetic aging as a risk factor for chronic obstructive pulmonary disease and decreased lung function in two prospective cohort studies. Aging (Albany NY), 2020, 12(16): 16539-16554.
18.	趙飄飄. 慢性阻塞性肺疾病綜合評估研究及臨床意義[D]. 中國醫科大學, 2013.
19.	張咪. 慢性阻塞性肺疾病頻繁急性加重表型的臨床與肺功能研究[D]. 吉林大學, 2020.
20.	殷曉娜, 楊萬春. CAT 和 mMRC 評分系統在慢性阻塞性肺疾病病情評估中的應用價值分析. 中國現代醫藥雜志, 2021, 23(3): 19-22.

1. Vogelmeier CF, Criner GJ, Martínez FJ, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. Arch Bronconeumol, 2017, 53(3): 128-149.
2. Cheng G, Zhang N, Wang Y, et al. Antibodies of IgG, IgA and IgM against human bronchial epithelial cell in patients with chronic obstructive pulmonary disease. Clin Lab, 2016, 62(6): 1101-1108.
3. Scambler T, Holbrook J, Savic S, et al. Autoinflammatory disease in the lung. Immunology, 2018, 154(4): 563-573.
4. Wen L, Krauss ES, Petersen F, et al. Autoantibodies in chronic obstructive pulmonary disease. Front Immunol, 2018, 25(9): 66.
5. 韋薇, 沈雅萍, 楊翌翔, 等. 血清中抗內皮細胞抗體檢測對狼瘡性腎炎患者的價值. 國際檢驗醫學雜志, 2017, 38(6): 822-824.
6. Moroncini G, Svegliati BS, Gabrielli A. Agonistic antibodies in systemic sclerosis. Immunol Lett, 2018, 195: 83-87.
7. 馬麗, 張璐, 張程, 等. 抗血管內皮細胞抗體在吸煙肺氣腫大鼠肺泡隔細胞凋亡中的作用及甲潑尼龍的干預效果. 廣東醫學, 2016, 37(10): 1447-1450.
8. 李佳藝, 張程, 李本雪, 等. 甲潑尼龍琥珀酸鈉對自身免疫性肺氣腫模型大鼠氧化應激和抗內皮細胞抗體的影響. 中國藥房, 2020, 31(10): 1208-1212.
9. 劉磊. 系統性紅斑狼瘡患者血清蛋白 S 與生長阻抑特異性蛋白 6 水平變化及與疾病活動度的相關性研究. 臨床和實驗醫學雜志, 2015, 14(24): 2052-2054.
10. 王艷, 陳燕, 季黎明, 等. 不同血清 25-羥維生素 D 水平的 2 型糖尿病患者頸動脈內膜中層厚度的變化. 臨床和實驗醫學雜志, 2016, 15(5): 445-447.
11. 中華醫學會呼吸病學分會慢性阻塞性肺疾病學組. 慢性阻塞性肺疾病診治指南(2013 年修訂版). 中華結核和呼吸雜志, 2013, 36(4): 255-264.
12. Legendre P, Régent A, Thiebault M, et al. Anti-endothelial cell antibodies in vasculitis: a systematic review. Autoimmun Rev, 2017, 16(2): 146-153.
13. Karayama M, Inui N, Suda T, et al. Antiendothelial cell antibodies in patients with COPD. Chest, 2010, 138: 1303-1308.
14. 包海鵬, 史琦, 閻玥, 等. 分子生物學標志物在 COPD 發病機制中的作用研究概況. 遼寧中醫雜志, 2019, 46(6): 1334-1338.
15. Taraseviciene SL, Douglas IS, Nana-Sinkam PS, et al. Is alveolar destruction and emphysema in chronic obstructive pulmonary disease an immune disease?. Proc Am Thorac Soc, 2006, 3(8): 687-690.
16. Neder JA, de-Torres JP, Milne KM, et al. Lung function testing in chronic obstructive pulmonary disease. Clin Chest Med, 2020, 41(3): 347-366.
17. Breen M, Nwanaji-Enwerem JC, Karrasch S, et al. Accelerated epigenetic aging as a risk factor for chronic obstructive pulmonary disease and decreased lung function in two prospective cohort studies. Aging (Albany NY), 2020, 12(16): 16539-16554.
18. 趙飄飄. 慢性阻塞性肺疾病綜合評估研究及臨床意義[D]. 中國醫科大學, 2013.
19. 張咪. 慢性阻塞性肺疾病頻繁急性加重表型的臨床與肺功能研究[D]. 吉林大學, 2020.
20. 殷曉娜, 楊萬春. CAT 和 mMRC 評分系統在慢性阻塞性肺疾病病情評估中的應用價值分析. 中國現代醫藥雜志, 2021, 23(3): 19-22.

Chinese Journal of Respiratory and Critical Care Medicine

Significance of continuous surveillance of anti-endothelial cell antibody in patients with chronic obstructive pulmonary disease

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content